Please select the option that best describes you:
Would you retreat a patient with docetaxel for metastatic castrate resistant prostate cancer if treated in hormone sensitive setting (metastatic disease) with good response three years ago but now has CRPC and has progressed on abiraterone?
Answer from: Medical Oncologist at Academic Institution
If the patient had a favorable response (presumably in setting of metastatic hormone sensitive prostate cancer), and it was well tolerated w/o evidence of chronic toxicities such as neuropathy I would definitely use docetaxel again. There is historic evidence for a docetaxel holiday in the met...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Retreating with docetaxel is reasonable, but my preference for the docetaxel pre-treated patient would be to use cabazitaxel based on data of efficacy after abiraterone (CARD trial) and after docetaxel (de Bono et al, 2010).